Investment Rating - The report gives a "Buy" rating for Zai Lab (09688) [10] Core Insights - Zai Lab is focusing on accelerating the clinical development of its core pipeline, with three key clinical studies for Zoci expected to catalyze growth in 2026 [3][4][10] - The company has successfully commercialized eight products in China, contributing to steady revenue growth and a significant reduction in losses [21][23] - Zai Lab's innovative pipeline includes promising candidates like KarXT, which is expected to change the treatment paradigm for schizophrenia, and Zoci, targeting small cell lung cancer [8][9][10][32] Summary by Sections 1. Company Overview - Zai Lab, founded in 2014, is an innovative biopharmaceutical company focused on addressing unmet medical needs in oncology, immunology, and neuroscience through the discovery, development, and commercialization of innovative products [17] 2. Clinical Pipeline - Zoci is undergoing three pivotal clinical studies in 2026, targeting second-line and first-line small cell lung cancer (SCLC) and neuroendocrine cancers (NECs) [4][37] - ZL-1503 has completed its first patient dosing and is expected to support phase 2 clinical development for atopic dermatitis [5][29] - The company is also advancing ZL-6201 and ZL-1222 in global clinical studies, with significant data expected in 2026 [5][29] 3. Market Potential - The approval of Zai Lab's products, including KarXT for schizophrenia, is anticipated to create new growth opportunities, with plans for commercialization in 2026 [23] - The company has seen a compound annual growth rate of 221.3% in revenue from 2018 to 2025, with core products like Niraparib leading sales [21][23] 4. Financial Projections - Revenue forecasts for 2026, 2027, and 2028 are projected at $483 million, $561 million, and $780 million respectively, with net losses expected to narrow significantly over the same period [10][13]

Investment Rating - The report upgrades the investment rating of ZTO Express (02057.HK) to "Strong Buy" with a target price of HKD 236, representing a 25% upside from the current price of HKD 188.50 [3][12]. Core Insights - The e-commerce express delivery industry is entering a new phase characterized by a shift from high growth to single-digit growth in parcel volume, prioritizing quality and price stability, and an increase in market share for leading companies [1][11]. - The report emphasizes the sustainability of the "anti-involution" trend in the industry, driven by customer demand for higher quality, regulatory requirements, and strategic needs [11][50]. - The industry landscape is expected to continue optimizing, with a focus on service quality rather than price competition, leading to a concentration of market share among leading firms [2][12]. Summary by Sections E-commerce Express Delivery Industry Transition - The industry is experiencing a significant change with parcel volume growth slowing from high rates to single digits, expected to stabilize around 8% by 2026 [1][19]. - Price adjustments are being implemented to counteract "involution," with significant price recovery observed since July 2025 [27][29]. - Leading companies are gaining market share, with ZTO's market share reaching 19.6% in Q4 2025, marking a year-on-year increase [1][45]. ZTO Express's Competitive Advantages - ZTO has made proactive capital investments that enhance its competitive edge, leading to significant cost advantages in parcel handling [6][14]. - The company maintains a leading position in terms of profitability and market share, with a focus on service quality and operational efficiency [12][14]. - ZTO's strategic emphasis on quality over quantity is expected to yield long-term benefits, allowing it to navigate the evolving market landscape effectively [48][49]. Financial Projections - The report adjusts the profit forecasts for ZTO, projecting net profits of CNY 91.5 billion, CNY 106.1 billion, and CNY 120.2 billion for 2025, 2026, and 2027 respectively [12][7]. - The adjusted net profit estimates correspond to price-to-earnings ratios of 13.6, 11.9, and 10.6 for the respective years [12][7]. - The anticipated market capitalization for ZTO in 2026 is projected at CNY 1639 billion (HKD 1859 billion) [12][7].

Investment Rating - The report maintains a "Buy" investment rating for the company [14] Core Views - The company has achieved significant production growth, with total copper production reaching 506,900 tons in 2025, a year-on-year increase of 27%. The revenue for 2025 is reported at $6.218 billion, reflecting a 39% increase compared to the previous year [5][10] - The main copper mine, Las Bambas, produced 410,800 tons in 2025, marking a 27% increase year-on-year, driven by operational efficiency improvements and strategic upgrades [6] - The company is expanding its operations, with Kinsevere and Khoemacau mines also showing production increases and ongoing expansion projects [7][9] Summary by Sections Financial Performance - The company reported a record revenue of $6.218 billion in 2025, up 39% year-on-year, with net profit after tax increasing to $955.2 million, a 161% rise [10] - EBITDA reached $3.412 billion, a 67% increase, while EBIT rose to $1.999 billion, up 102% [10] Production and Cost Guidance - Las Bambas is expected to produce between 380,000 to 400,000 tons of copper in 2026, with C1 costs projected between $1.20 to $1.40 per pound [6] - Kinsevere's production is guided at 65,000 to 75,000 tons for 2026, with C1 costs between $2.50 to $2.90 per pound [8] - Khoemacau's production guidance for 2026 is set at 48,000 to 53,000 tons, with C1 costs expected to be between $2.00 to $2.30 per pound [9] Capital Expenditure - The total capital expenditure for 2025 was $1.081 billion, with significant investments in Las Bambas and Khoemacau expansion projects. The expected capital expenditure for 2026 is projected to be between $1.6 billion to $1.7 billion [11][12] Future Outlook - The company forecasts revenues of $7.046 billion in 2026, with net profit expected to reach $984 million, reflecting continued growth in production and favorable market conditions [14]

Investment Rating - The report maintains a "Strong Buy" rating for 加科思-B (01167.HK) [2] Core Views - 加科思 has released its 2025 annual performance report, showcasing the efficacy data of its pan-KRAS inhibitor JAB-23E73, which demonstrates potential as a best-in-class treatment [2] - The company is expected to achieve significant revenue growth in the coming years, with projected revenues of 670 million in 2026, 493 million in 2027, and 455 million in 2028, reflecting a substantial recovery from a revenue of 54 million in 2025 [4] - The net profit is projected to turn positive in 2026, with estimates of 417 million, 234 million, and 167 million for the years 2026, 2027, and 2028 respectively [4] - The target price for the stock is set at 11.65 HKD, compared to the current price of 6.99 HKD, indicating a significant upside potential [4] Financial Summary - Total revenue for 2025 is reported at 54 million, with a year-on-year decline of 65.6%, followed by an expected increase of 1,152.2% in 2026 [4] - The company anticipates a net profit of -146 million in 2025, transitioning to a profit of 417 million in 2026, marking a growth of 385.5% [4] - Earnings per share (EPS) is projected to improve from -0.18 in 2025 to 0.53 in 2026 [4] - The price-to-earnings (P/E) ratio is expected to shift from -33 in 2025 to 12 in 2026, indicating a positive market sentiment [4] Clinical Development Insights - The pan-KRAS inhibitor JAB-23E73 has shown promising efficacy data, with an overall response rate (ORR) of 38.5% in a domestic pancreatic cancer subgroup [8] - The company is advancing its clinical trials, with plans to initiate a Phase II trial for JAB-23E73 in China in the first half of 2026 [8] - The next-generation ADC platform is expected to expand into multiple targets and indications, with significant innovations underway [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown significant growth in copper production, with a total production of 506,900 tons in 2025, representing a year-on-year increase of 27%. The revenue for 2025 reached $6.218 billion, up 39% year-on-year, with net profit after tax soaring to $955 million, a 161% increase [5][10] - The main copper mine, Las Bambas, achieved a production of 410,800 tons in 2025, marking a 27% increase from the previous year, driven by operational efficiency improvements and strategic upgrades [6] - The company is expanding its operations, with Kinsevere and Khoemacau mines also showing production increases and ongoing expansion projects [7][9] Summary by Sections Basic Data - Current stock price is HKD 8.45, with a total market capitalization of HKD 1,025.9 billion and total shares outstanding of 12,140.5 million [2] Market Performance - The company has experienced a strong financial performance, with record revenue and operating cash flow [10] Investment Highlights - Las Bambas mine's production reached 410,800 tons in 2025, with a C1 cost of $1.12 per pound, down from $1.51 per pound in 2024 [6] - Kinsevere mine produced 52,800 tons in 2025, with a C1 cost of $3.12 per pound, showing a decrease from $3.26 per pound in 2024 [7] - Khoemacau mine's production was 42,100 tons in 2025, with a C1 cost of $1.97 per pound, down from $2.54 per pound in 2024 [9] Financial Performance - The company achieved record revenue of $6.218 billion in 2025, with EBITDA reaching $3.412 billion, a 67% increase year-on-year [10] - The forecast for 2026-2028 indicates continued revenue growth, with projected revenues of $7.046 billion in 2026 and net profits of $984 million [14] Capital Expenditure - Capital expenditure for 2025 was $1.081 billion, with plans for $1.6 billion to $1.7 billion in 2026, focusing on expansion projects [11][12] Future Outlook - The company expects to maintain strong production levels and profitability, with a projected C1 cost for Las Bambas in 2026 between $1.20 and $1.40 per pound [6] - The Khoemacau expansion project is expected to enhance production capacity significantly, with first copper concentrate output anticipated in mid-2028 [13]

Investment Rating - The report assigns a "Buy" rating for the company, InnoScience [1]. Core Insights - InnoScience is a leading player in the global GaN power semiconductor market, recognized for its advanced technology and comprehensive layout in the third-generation semiconductor sector. The company has achieved significant market share, with a revenue share of 33.7% and a shipment volume share of 42.4% in 2023 [11][12]. - The company is expected to experience strong revenue growth driven by increasing demand in various sectors, including data centers and humanoid robots, with projected revenues of RMB 14.2 billion, RMB 27.3 billion, and RMB 44.2 billion for 2025, 2026, and 2027 respectively [1][15]. Summary by Sections 1. Market Position - InnoScience is the first company globally to achieve mass production of 8-inch GaN-on-Si wafers and has become the top supplier in terms of GaN power semiconductor shipments and revenue [11]. - The company operates two 8-inch GaN wafer production bases in Suzhou and Zhuhai, with plans to increase monthly production capacity from 13,000 wafers in 2024 to 70,000 wafers by 2030 [12]. 2. Financial Performance - The company has shown explosive revenue growth, with revenues increasing from RMB 0.68 billion in 2021 to RMB 8.28 billion in 2024, reflecting a compound annual growth rate of 129.9% from 2021 to 2024 [15]. - Despite being in a loss-making position, the company has been reducing its losses, with a projected net profit of RMB 6.76 billion by 2027 [1][15]. 3. Downstream Applications - The demand for GaN power semiconductors is expanding across various sectors, including consumer electronics, data centers, automotive electronics, renewable energy, and humanoid robots [28]. - The global GaN power semiconductor market is expected to grow from RMB 18 billion in 2023 to RMB 501 billion by 2028, with a market penetration increase from 0.5% to 10.1% [31]. 4. Product Development and Strategy - InnoScience has developed a comprehensive product line covering voltage ranges from 15V to 1200V, targeting multiple application scenarios [12]. - The company has established strategic partnerships with major clients such as OPPO and NVIDIA, enhancing its market position and product integration capabilities [42][50].

Investment Rating - The report assigns a "Buy" rating for the company, InnoScience [1] Core Insights - InnoScience is a leading player in the global GaN power semiconductor market, recognized for its advanced technology and comprehensive layout in the third-generation semiconductor sector [11][12] - The company has achieved significant revenue growth, with projections indicating a strong upward trend in both revenue and net profit over the next few years [15][27] - The global GaN power semiconductor market is expected to grow substantially, with forecasts suggesting an increase from RMB 18 billion in 2023 to RMB 501 billion by 2028, indicating a rising market penetration [31][32] Summary by Sections 1. Company Overview - InnoScience is the first company to achieve mass production of 8-inch GaN-on-Si wafers and currently holds the largest market share in GaN power semiconductor shipments and revenue [11] - The company operates two 8-inch GaN wafer production bases in Suzhou and Zhuhai, with plans to increase monthly production capacity from 13,000 wafers in 2024 to 70,000 wafers by 2030 [12] 2. Financial Performance - Revenue has shown explosive growth, with a compound annual growth rate (CAGR) of 129.9% from 2021 to 2024, driven by the release of 8-inch capacity and the launch of products across multiple scenarios [15] - The company is expected to achieve revenues of RMB 14.2 billion, RMB 27.3 billion, and RMB 44.2 billion from 2025 to 2027, with net profits projected to turn positive by 2027 [1][15] 3. Market Position and Strategy - InnoScience's strategy focuses on "8-inch mass production + full voltage coverage + multi-scenario deployment," which supports continuous technological iteration and product upgrades [12] - The company has established deep collaborations with major clients such as OPPO and NVIDIA, enhancing its competitive edge in various applications including consumer electronics, data centers, and automotive electronics [12][50] 4. Industry Outlook - The demand for GaN power semiconductors is expected to rise significantly due to the increasing need for efficient power supply devices across various industries, driven by the fourth industrial revolution [28] - The automotive sector is projected to see substantial growth, with the market for GaN power semiconductors in electric vehicles expected to grow from RMB 40 million in 2019 to RMB 6.94 billion in 2023, reflecting a CAGR of 266% [54]

Investment Rating - The report maintains a "Strong Buy" rating for 加科思-B (01167.HK) with a target price of HKD 11.65, compared to the current price of HKD 6.99 [2][4]. Core Insights - 加科思 has released its 2025 annual performance report, showcasing promising efficacy data for its pan-KRAS inhibitor JAB-23E73, which is considered to have best-in-class potential [2]. - The company expects to turn profitable in 2026, with significant revenue growth anticipated from its innovative drug pipeline, particularly the pan-KRAS inhibitor [8]. - The report highlights the company's strong cash reserves, projected to exceed HKD 2 billion by the end of Q1 2026, which will support its clinical trials and operational activities [8]. Financial Summary - Total revenue for 2025 is reported at HKD 54 million, with a projected increase to HKD 670 million in 2026, reflecting a year-on-year growth rate of 1,152.2% [4]. - The net profit attributable to shareholders is expected to be HKD 417 million in 2026, a significant turnaround from a loss of HKD 146 million in 2025 [4]. - Earnings per share (EPS) is projected to improve from -0.18 in 2025 to 0.53 in 2026, indicating a positive shift in profitability [4]. Clinical Development and Market Position - The pan-KRAS inhibitor JAB-23E73 has shown an overall response rate (ORR) of 38.5% in a domestic pancreatic cancer subgroup, outperforming competitors in the same class [8]. - The company is advancing its next-generation antibody-drug conjugate (ADC) platforms, which are expected to expand its treatment options and market reach [8]. - 加科思's KRAS G12C inhibitor, 戈来雷塞, has already contributed revenue and is expanding its indications, with sales expected to grow following its inclusion in medical insurance [8].

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expectation that the stock will outperform the market by more than 15% over the next 12 months [8]. Core Insights - The company is undergoing continuous organizational streamlining to enhance operational efficiency in response to ongoing pressures in the real estate market, which has affected both second-hand and new housing transactions [8]. - Due to a one-time cost increase at the end of the year, the profit forecast for Q4 2025 has been adjusted downwards, with an expected operating profit of 400 million RMB, a year-on-year decrease of 76% [8]. - The company is expected to achieve an adjusted operating profit of 7 billion RMB in 2026, reflecting a 62% year-on-year increase, despite a cautious market outlook [8]. - The adjusted net profit forecast for 2026 is projected to be 6.6 billion RMB, a 31% increase year-on-year, driven by improved operational efficiency [8]. - The report highlights the company's strong cash position of 73.9 billion RMB and suggests a valuation based on a 20x adjusted PE ratio, leading to a target price of 58.46 HKD per share [8]. Financial Forecast Summary - The company's main revenue is projected to be 77.8 billion RMB in 2023, increasing to 93.5 billion RMB in 2024, with a growth rate of 28.2% and 20.2% respectively [2]. - The adjusted net profit is expected to be 9.8 billion RMB in 2023, decreasing to 7.2 billion RMB in 2024, with a significant drop of 30.1% in 2025, followed by a recovery to 8.7 billion RMB in 2027 [2][9]. - The adjusted EPS is forecasted to be 2.63 RMB in 2023, declining to 1.99 RMB in 2024, and then recovering to 2.50 RMB by 2027 [2][9]. - The company's EBITDA is expected to decrease from 8 billion RMB in 2023 to 6.6 billion RMB in 2024, with a further decline to 4 billion RMB in 2025 before rebounding to 9.2 billion RMB in 2027 [2][9].

Investment Rating - The report maintains a "Buy" rating for Tencent Holdings [1][10] Core Insights - Tencent is positioned as a core beneficiary in the AI era, leveraging its super entrance and ecological barriers for further evolution [7] - The company has a solid financial foundation and core scenarios that support its AI strategy, indicating strong potential for latecomers [9][12] - Tencent's AI capabilities are being enhanced through organizational restructuring and the recruitment of top talent, improving the efficiency of AI research and commercialization [9][40] - The company has established a leading position in 3D and image generation capabilities within the industry [9][40] - The ecological value of Tencent's AI will be amplified in the Agent era, with significant impacts on existing business lines such as advertising and gaming [9][12] Financial Data and Profit Forecast - Revenue projections for Tencent are as follows: - 2023: 609 billion - 2024: 660 billion - 2025E: 755.6 billion - 2026E: 848.8 billion - 2027E: 929.9 billion - Year-on-year growth rates are projected at 9.8% for 2023, 8.4% for 2024, 14.4% for 2025, 12.3% for 2026, and 9.6% for 2027 [8] - Adjusted net profit forecasts are: - 2023: 157.7 billion - 2024: 222.7 billion - 2025: 260.2 billion - 2026: 296.9 billion - 2027: 337.1 billion - Year-on-year growth rates for adjusted net profit are 36.4% for 2023, 41.2% for 2024, 16.9% for 2025, 14.1% for 2026, and 13.5% for 2027 [8] Valuation and Target Price - The overall target valuation for Tencent is set at 61,412 billion RMB, corresponding to a target price of 765 HKD per share, indicating a potential upside of 40% from the closing price on March 12, 2026 [10][12]